3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoid Tumor
1
Interventions
Everolimus
8
lanreotide
3
gallium Ga 68 dotatate
3
Octreotide
3
Nivolumab
3
pasireotide
2
lutetium Lu 177 dotatate
2
cabozantinib
2
Temozolomide
2
Sunitinib
2
Ga(III)-DOTATOC
2
Erlotinib Hydrochloride
2
Capecitabine
2
zimberelimab
1
veliparib
1
telotristat ethyl
1
recombinant interferon alpha 2b-like protein
1
pertuzumab
1
pembrolizumab
1
olaparib
1
nintedanib
1
ibrutinib
1
ganitumab
1
fosbretabulin
1
epothilone B
1
cixutumumab
1
arginyllysine
1
TKM-080301
1
Sorafenib
1
Serotonin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoid Tumor
×
zimberelimab
×
NET
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled